Posted by
2019 Clinical TMS Society Annual Meeting

2019 Clinical TMS Society Annual Meeting

See you there! PASWFL is excited to be attending the Clinical TMS Society Annual Meeting in Vancouver, BC. We are excited to bring you the 2019 Clinical TMS Society Annual Meeting. Over the last 6 years, our meeting has quadrupled in size as over 532 attendees joined us in 2018. We look forward to another great […]

Posted by
FDA panels back intranasal esketamine for refractory depression

FDA panels back intranasal esketamine for refractory depression

Each disposable intranasal delivery device contains 28 mg esketamine; it will come in prepackaged units of one, two, or three devices to deliver the prescribed doses of 28 mg, 56 mg, or 84 mg, respectively. The device does not require priming and, after use, contains only about 30 microliters of residual medication. Its interlocking design, […]

Posted by
FDA Committees Vote on Esketamine Nasal Spray for Treatment-Resistant Depression

FDA Committees Vote on Esketamine Nasal Spray for Treatment-Resistant Depression

The Food and Drug Administration (FDA)’s Psychopharmacologic Drug Advisory Committee and Drug Safety and Risk Management Advisory Committee voted in favor (14 yes, 2 no, 1 abstain) of the approval of esketamine nasal spray (Spravato; Janssen) for the treatment of adult patients with treatment-resistant depression (TRD). The decision was based on data from five Phase […]

Posted by
Esketamine Evaluated in MDD Patients at Imminent Risk for Suicide

Esketamine Evaluated in MDD Patients at Imminent Risk for Suicide

Janssen announced new findings from a Phase 2 study evaluating esketamine nasal spray in patients with major depressive disorder who were at imminent risk for suicide. The findings were published in the American Journal of Psychiatry. Esketamine nasal spray is an investigational glutamate receptor modulator that is thought to help restore synpatic connections in brain cells in patients […]

Posted by
Intranasal Esketamine Evaluated in Treatment-Resistant Depression

Intranasal Esketamine Evaluated in Treatment-Resistant Depression

(HealthDay News) — Esketamine seems to be efficacious and safe for patients with treatment-resistant depression (TRD), according to a study published online Dec. 27 in JAMA Psychiatry. Ella J. Daley, M.D., from Janssen Research & Development LLC in Titusville, N.J., and colleagues conducted a phase 2, double-blind, doubly randomized, delayed-start, placebo-controlled study to examine the efficacy, […]

Posted by
“Brain Zaps” Reported by Some Following Antidepressant Discontinuation

“Brain Zaps” Reported by Some Following Antidepressant Discontinuation

Abrupt discontinuation of an antidepressant was found to be the most likely cause of brain zaps A recently published article discusses the characteristics, symptoms, and effects on quality of life associated with brain zaps, the electrical phenomenon that can occur following antidepressant discontinuation. The study authors explained, “In some patients, stopping or reducing the dose of an […]

Posted by
Ketamine as a Treatment for Postpartum Depression

Ketamine as a Treatment for Postpartum Depression

Abstract Postpartum depression (PPD) affects over 10% of new mothers and adversely impacts the health of offspring. One of the greatest risk factors for PPD is prepregnancy stress but the underlying biological mechanism is unknown. Here we constructed an animal model which recapitulated prepregnancy stress induced PPD and tested the role of Akt-mTOR signaling in […]

Posted by
TMS for Perinatal Depression

TMS for Perinatal Depression

By Paul Croarkin, DO, Research Committee Co-chair and Philip Janicak, MD, Research Committee Member Introduction Perinatal depressions are serious, debilitating conditions which are often under-recognized; and, even when properly diagnosed, often sub-optimally treated.  Notably, they can contribute to problematic maternal behaviors such as substance use, poor self-care, non-adherence to prenatal care, and a heightened risk for […]

Posted by
Ketamine Found Effective for Patients With Anxious Treatment-Resistant Depression

Ketamine Found Effective for Patients With Anxious Treatment-Resistant Depression

Patients with anxious depression—major depressive disorder (MDD) with high levels of anxiety—are known to have a poorer response to commonly used antidepressants than those with MDD. A small study published in Depression & Anxiety now suggests intravenous (IV) ketamine may be able to reduce symptoms in patients with anxious depression. The study found patients with and without anxious depression […]